Ticker

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meet

OSE Immunotherapeutics Evolves its Leadership Team Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the…

Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announces its participation in the following investor conferences: Mardi de la Bourse – Lyon Pôle Bourse (retail event) April 7, 2026 – CRCC Lyon, France Marc Le Bozec, Chief…

Nantes, France, March 16, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026.   Information Date*  2025 Full-Year Financial Update and Statements April 29, 2026 2026 1Q Cash Position April 30, 2026 Annual General Meeting June 24, 2026 2026 First-Half Financial Update and Statements September 28, 2026 2026 3Q Cash Position October 27, 2026…

Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic plan No impact on cash runway or financing strategy as no milestone associated with these programs was expected within this three-year timeframe Focused investment on high‑value late‑stage assets Lusvertikimab and Tedopi®  Multiple clinical catalysts expected from 2026 to 2028…